title: Use of healthy volunteers drives clinical oncology drug development decision making.
authors.affiliation: Department of Project Leadership and Management, Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, USA. marian.iwamoto@merck.com
authors.forename: M
authors.initials: M
authors.lastname: Iwamoto
authors.forename: R
authors.initials: R
authors.lastname: Iannone
authors.forename: J A
authors.initials: JA
authors.lastname: Wagner
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002986:Clinical Trials as Topic / Q000379:methods; D003657:Decision Making; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D004347:Drug Interactions; D023381:Endpoint Determination; D064368:Healthy Volunteers; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents